Saxenda vs Wegovy: Daily vs Weekly GLP-1 Injection
Liraglutide vs semaglutide for weight loss — dosing, efficacy, and tolerability.
Key takeaways
Wegovy (semaglutide) is dosed once weekly and produced roughly 15% average body weight loss in the STEP-1 trial, while Saxenda (liraglutide) is a daily injection and averaged about 8% weight loss in the SCALE trial.
Saxenda and Wegovy share the same drug class (GLP-1 receptor agonists) and similar side effect profile, but the daily dosing schedule and lower efficacy of Saxenda mean Wegovy has become the default first-line option for most patients.
Saxenda may still make sense for adolescents 12 and older, patients who do not tolerate semaglutide, those whose insurance covers liraglutide but not semaglutide, or anyone who prefers daily dosing for behavioral pacing.
Both drugs are FDA-approved for chronic weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia.
Side effects of both drugs are mainly gastrointestinal — nausea, vomiting, diarrhea, and constipation — and both carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies.
Only your prescriber can decide which GLP-1 is appropriate for you; GLP1Zoom does not prescribe or sell medication — we compare options and redirect to licensed providers.
Saxenda vs Wegovy at a glance
and are both injectable GLP-1 receptor agonists from Novo Nordisk approved by the FDA for chronic weight management. They work on the same biological pathway — mimicking the gut hormone GLP-1 to slow gastric emptying, lower appetite, and reduce food intake — but they are different molecules with different dosing schedules and different average weight loss in their pivotal trials.
Saxenda contains liraglutide and is injected once a day. It was the first GLP-1 receptor agonist approved for weight loss, receiving FDA clearance in December 2014. Wegovy contains semaglutide, a longer-acting molecule from the same family, and was approved in June 2021. Wegovy is injected once a week, which most patients find easier to stick with than a daily shot.
On efficacy, the gap is meaningful. In the SCALE trial of liraglutide 3.0 mg, adults without diabetes lost roughly 8% of body weight on average after 56 weeks. In the STEP-1 trial of semaglutide 2.4 mg, the comparable figure was about 14.9% at 68 weeks. That difference — combined with weekly versus daily injections — explains why most new prescriptions today are for Wegovy rather than Saxenda.
Both Saxenda and Wegovy belong to the GLP-1 receptor agonist (GLP-1 RA) class. Glucagon-like peptide-1 is a hormone the gut releases after meals. It tells the pancreas to secrete insulin, slows how fast the stomach empties, and signals the brain — particularly the hypothalamus — that you are full. GLP-1 RAs mimic that hormone but stay in the body much longer than natural GLP-1, which is broken down within minutes.
Liraglutide (Saxenda) has a half-life of roughly 13 hours, which is why it has to be injected every day. Semaglutide (Wegovy and ) has a half-life of about 7 days thanks to a fatty acid side chain that lets it bind tightly to albumin in the blood. That longer half-life is what makes once-weekly dosing possible and gives semaglutide a steadier drug level between injections.
The net clinical effect of both drugs is similar in direction: less hunger, smaller portions, fewer cravings, and slower digestion. The size of the effect, however, is different. Head-to-head data from the STEP-8 trial directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily over 68 weeks. Semaglutide produced a mean weight loss of about 15.8% versus 6.4% for liraglutide — a roughly two-fold difference in the same trial population.
Efficacy: what the trials actually show
The pivotal trial for Saxenda was SCALE Obesity and Prediabetes, published in the New England Journal of Medicine in 2015. In adults with a BMI of 30 or more (or 27 or more with a comorbidity), liraglutide 3.0 mg plus diet and exercise produced a mean weight loss of about 8.0% at 56 weeks versus 2.6% with placebo. Around 63% of patients on liraglutide lost at least 5% of body weight, and about 33% lost at least 10%.
The pivotal trial for Wegovy was STEP-1, also published in NEJM, in 2021. Adults without diabetes on semaglutide 2.4 mg plus lifestyle intervention lost a mean of about 14.9% of body weight at 68 weeks versus 2.4% on placebo. About 86% of semaglutide patients lost at least 5%, around 69% lost at least 10%, and roughly 32% lost at least 20% — a level of weight loss not previously seen with any GLP-1 monotherapy.
Both numbers come from intent-to-treat analyses and represent average outcomes — individual results vary widely. People with type 2 diabetes typically lose less weight on either drug than people without diabetes, a pattern seen across the SCALE-Diabetes and STEP-2 trials. Your prescriber will weigh these averages against your starting weight, metabolic profile, and treatment history.
Dosing schedule and titration
Saxenda is injected subcutaneously once a day, typically into the abdomen, thigh, or upper arm, and can be given at any time independent of meals. Wegovy is injected subcutaneously once a week on the same day each week, again into the abdomen, thigh, or upper arm. Both come in multi-dose pens with fixed dose settings.
Both drugs require a gradual titration — starting at a low dose and stepping up over several weeks — to reduce gastrointestinal side effects. Your prescriber will determine the appropriate escalation schedule and target maintenance dose based on tolerability. Skipping titration steps tends to drive more nausea and vomiting, so most clinicians stick closely to the FDA-approved schedule on each drug's label.
From a behavioral standpoint, weekly dosing is usually easier to maintain. Daily injections give 7 chances per week to forget or skip a dose, and patients often report injection fatigue over months of therapy. That said, some patients prefer a daily routine because it is easier to remember when paired with another daily habit, and a missed daily dose has less impact on blood levels than a missed weekly dose.
Side effects and safety
Saxenda and Wegovy share the same overall safety profile because they target the same receptor. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion. These tend to be worst during dose escalation and improve as the body adjusts. According to FDA prescribing information, nausea affected roughly 39% of Saxenda patients and around 44% of Wegovy patients in pivotal trials.
Both drugs carry an FDA boxed warning for thyroid C-cell tumors based on rodent studies. Whether this risk translates to humans is uncertain, but the labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both labels also warn about pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia (especially with insulin or sulfonylureas), and serious hypersensitivity reactions.
Newer post-marketing reports have raised questions about additional risks across the GLP-1 class, including ileus, gastroparesis, and changes in mood. The FDA continues to update labels as evidence accumulates. If you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction, the labels direct patients to seek medical care immediately and contact their prescriber.
Cost, coverage, and access
Both Saxenda and Wegovy have list prices in the same broad range — historically around $1,300 to $1,600 per month before insurance, according to Novo Nordisk's published US list prices. Actual out-of-pocket cost depends heavily on commercial insurance coverage, employer formulary, manufacturer savings cards, and whether obesity is treated as a covered diagnosis under your plan.
Medicare Part D historically did not cover anti-obesity medications, although coverage for related cardiovascular indications has begun to shift this. Medicaid coverage varies state by state. Commercial plans may cover one drug and not the other, or may require step therapy where you must try and fail a less expensive option first. Your prescriber and pharmacist can run a benefits check before you commit to either drug.
For cash-pay patients, both drugs are expensive enough that many people consider compounded GLP-1 alternatives. It is important to know that compounded semaglutide and compounded liraglutide are not FDA-approved as finished products — they are mixed by individual pharmacies under FDA compounding rules, and the FDA has issued warnings about quality, purity, and dosing errors in some compounded GLP-1 products. GLP1Zoom does not prescribe or sell medication — we compare options and redirect to licensed providers.
Who Saxenda may still fit
Despite Wegovy's better average weight loss, Saxenda still has clear use cases. Saxenda is FDA-approved for adolescents aged 12 to 17 with obesity, supported by a 56-week pediatric trial showing significantly greater BMI reduction with liraglutide than placebo. Wegovy was later approved for adolescents 12 and older as well, but Saxenda has the longer pediatric track record and is sometimes preferred by clinicians familiar with it.
Saxenda can also make sense when Wegovy is unavailable due to shortages, when insurance covers liraglutide but not semaglutide, or when a patient does not tolerate semaglutide at the doses needed for meaningful weight loss. Some patients who experience strong side effects on weekly semaglutide find the shorter-acting liraglutide easier to manage because the drug level falls between daily injections.
Pregnancy, planned pregnancy, breastfeeding, severe gastroparesis, a history of pancreatitis, and the thyroid contraindications listed above are reasons either drug may be inappropriate. Your prescriber will weigh your full medical history, current medications, and prior weight-loss treatments to decide whether Saxenda, Wegovy, or a non-GLP-1 option is the right fit.
Who Wegovy usually fits better
For most adults newly starting a GLP-1 for weight management, Wegovy is the more common first choice. The reasons are the larger average weight loss in trials, the more convenient weekly dosing, and the newer cardiovascular outcomes data. In the SELECT trial of adults with overweight or obesity and pre-existing cardiovascular disease (without diabetes), semaglutide 2.4 mg reduced major adverse cardiovascular events by about 20% over a mean follow-up of roughly 40 months versus placebo.
Based on SELECT, the FDA expanded Wegovy's label in 2024 to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. Saxenda does not carry an equivalent cardiovascular indication. If you have known heart disease and obesity, that label difference may be relevant to your prescriber's decision.
Wegovy is also often preferred by patients who travel frequently, work shift schedules, or have difficulty remembering daily medications. The trade-off is that side effects from a missed or delayed weekly dose can feel more pronounced when therapy is resumed, whereas daily Saxenda allows finer-grained adjustment if tolerability becomes a problem.
How they compare to other GLP-1 and GIP/GLP-1 drugs
Saxenda and Wegovy are not the only injectable options for weight management. is semaglutide at lower doses approved for type 2 diabetes; it is the same molecule as Wegovy but is not FDA-approved for weight loss as a standalone indication. Mounjaro and Zepbound contain tirzutide, a dual GIP/GLP-1 receptor agonist from Eli Lilly. In the SURMOUNT-1 trial, tirzutide 15 mg produced mean weight loss of about 20.9% over 72 weeks — higher than semaglutide in indirect comparisons.
Choosing among these is not just a numbers game. Cost, insurance coverage, supply, side effect tolerance, comorbid conditions, and personal preference all matter. Some patients respond better to one molecule than another for reasons not yet fully understood. Switching between GLP-1 drugs is common in clinical practice and is something your prescriber can discuss if your first choice is not working.
If you are deciding between Saxenda and Wegovy specifically, the most useful question is usually not which is better in the abstract but which is better given your insurance, your tolerability, and your goals. A licensed clinician can walk you through that decision and order the appropriate labs and follow-up. GLP1Zoom helps you compare published trial data and connect with providers; we do not prescribe.
Frequently asked questions
Is Wegovy stronger than Saxenda?
In head-to-head data from the STEP-8 trial, semaglutide 2.4 mg (Wegovy) produced roughly 15.8% mean weight loss versus about 6.4% for liraglutide 3.0 mg (Saxenda) over 68 weeks. So on average, yes, Wegovy produces more weight loss. Individual response varies, however, and some patients tolerate liraglutide better than semaglutide. Your prescriber will weigh efficacy against tolerability and access.
Can I switch from Saxenda to Wegovy?
Switching between GLP-1 receptor agonists is common in practice, but the timing, starting dose, and titration on the new drug should be decided by your prescriber. There is no universal protocol — clinicians typically consider how long you have been on Saxenda, your current tolerability, and any side effects before transitioning to Wegovy. Do not self-switch; the drugs use different dose strengths and pens.
Why is Saxenda a daily injection when Wegovy is weekly?
The difference is molecular. Liraglutide (Saxenda) has a half-life of about 13 hours, so blood levels drop quickly and require daily dosing to stay effective. Semaglutide (Wegovy) was engineered with a fatty acid side chain that binds tightly to albumin in the blood, extending its half-life to roughly 7 days. That longer half-life is what makes once-weekly dosing possible and gives semaglutide steadier drug levels.
Are the side effects of Saxenda and Wegovy the same?
They are broadly similar because both drugs target the same GLP-1 receptor. The most common side effects of both are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually worst during dose escalation. Both carry an FDA boxed warning for thyroid C-cell tumors observed in rodents and label warnings for pancreatitis, gallbladder disease, and acute kidney injury. Rates of nausea were slightly higher with Wegovy in pivotal trials.
Does insurance cover Saxenda or Wegovy?
Coverage depends heavily on your specific commercial plan, employer formulary, and state. Many plans cover one drug and not the other, or require step therapy. Medicare Part D historically did not cover anti-obesity medications, although that is evolving for cardiovascular indications under the Wegovy label. Medicaid coverage varies by state. A benefits check by your prescriber's office or pharmacy before starting therapy can save substantial out-of-pocket cost.
Is compounded liraglutide or compounded semaglutide a cheaper alternative?
Compounded versions of liraglutide and semaglutide are not FDA-approved as finished products. They are mixed by individual compounding pharmacies under FDA compounding rules, and the FDA has issued warnings about quality, purity, and dosing errors in some compounded GLP-1 products. They may cost less than brand Saxenda or Wegovy, but the trade-offs in oversight, sourcing, and ingredient verification are real. Discuss the risks with a licensed clinician.
Can teenagers use Saxenda or Wegovy?
Both are FDA-approved for adolescents 12 and older with obesity. Saxenda was approved for ages 12 to 17 first, supported by a 56-week pediatric trial. Wegovy received pediatric approval later based on its own adolescent trial showing significant BMI reduction versus placebo. Whether either is appropriate for a specific adolescent depends on growth status, comorbidities, family history, and prescriber judgment. Pediatric obesity treatment should be supervised by a clinician familiar with weight management in young people.
How long do I have to stay on Saxenda or Wegovy?
Both Saxenda and Wegovy are FDA-approved for chronic weight management, meaning long-term use as long as the drug is providing benefit and is tolerated. Stopping either drug usually leads to gradual weight regain, as shown in the STEP-4 trial extension for semaglutide. Your prescriber will discuss the duration of therapy, any treatment breaks, and how to monitor weight, labs, and side effects on an ongoing basis.
We cite primary sources — FDA-approved prescribing information (DailyMed), ClinicalTrials.gov registry IDs, and peer-reviewed publications — over secondary commentary. Every medical claim is re-checked at least every 6 months. Spot something wrong? Tell us. See our full editorial policy.